ETFs positioned on Insmed Incorporated

Name Varia. Jan 1. Weight AuM
+2.55%0.01% 7 M€
-5.90%0.01% 293,477 M€
-0.25%0.01% 35 M€
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
Employees
1,664
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
159.59USD
Average target price
212.79USD
Spread / Average Target
+33.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. INSM Stock
  4. ETFs Insmed Incorporated